Dopamine receptor agonists for treating prolactinomas

Bibliography

• VANCE ML, THORNER MO: Prolactin: hyperprolactnemic syndromes and management. In: Textbook of Endocrinology 2nd edn. DeGroot LJ (ed). WB Saunders, Philadelphia, USA (1989):408–418.
   Google Scholar
• BURGESS JR, SHEPARD JJ, PARAMESWARAN V et al.: Spectrum of pituitary disease in multiple endocrine neoplasia Type 1: clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. j. Clin. Endocrinol. Metab. (1996) 81:2642–2646.
   PubMed Web of Science ®Google Scholar
• BURGESS JR, SHEPARD JJ, PARAMESWARAN V et al.: Prolactinomas in a large kindred with multiple endocrine neoplasia Type 1: clinical features and inheritance pattern. j. Clin. Endocrinol. Metab. (1996) 81:1841–1845.
   PubMed Web of Science ®Google Scholar
• COSTELLO RT: Subclinical adenoma of thepituitary gland. Am. J. Pathol. (1936) 12:205–216.
   PubMedGoogle Scholar
• BURROW GN, WORTZMAN G, REWCASTLE NB et al: Microadenomas of the pituitary gland and abnormal sellar tomograms in an unselected autopsy series. N Engl. J. Med (1980) 304:156–158.
   Web of Science ®Google Scholar
• COLAO A, LOMBARDI G: Growth hormone and prolactin excess. Lancet (1998) 352:1455–1461.
   PubMed Web of Science ®Google Scholar
• ••The most recent review onhyperprolactinaemia.
   Google Scholar
• CALLE-RODRIGUE RD, GIANNINI C, SCHEITHAUER BW et al.: Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin. Proc. (1998) 73:1046–1052.
   PubMed Web of Science ®Google Scholar
• DELGRANGE E, TROUILLAS J, MATTER D, DONCKIERJ, TOURNIAIRE J: Sex-related difference in the growth of prolactinomas : a clinical and proliferation marker study. J. CM]. Endocrinol Metab. (1997) 82:2102–2107.
   PubMed Web of Science ®Google Scholar
• CUNNAH D, BESSER M: Management of prolactinomas. Clin. Endocrinol (1991) 34:231–235.
   PubMed Web of Science ®Google Scholar
• MOLITCH ME, THORNER MO, WILSON C: Management of prolactinomas. .1. Clin. Endocrinol Metab. (1997) 82:996–1000.
   PubMed Web of Science ®Google Scholar
• ••The surgeon's versus the endocrinologist'sview on the treatment of hyperprolactinaemia.
   Google Scholar
• BLAKE TYRRELL J, LAMBORN KR, HANNEGAN LT, APPLEBURY CB, WILSON CB: Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery (1999) 44(2):254–263.
   PubMed Web of Science ®Google Scholar
• COLAO A, ANNUNZIATO L, LOMBARDI G: Treatment of prolactinomas. Ann. Merl (1998) 30:452–459.
   PubMed Web of Science ®Google Scholar
• VERHELST J, ABS R, MATTER D et al.: 1999 Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. .1. Clin. Endocrinol Metab. 84: 2518–2522.
   Google Scholar
• •The largest cohort of patients reported so far with the analysis of positive predictive factors for treatment response.
   Google Scholar
• CANNAVO S, CURT() L, SQUADRITO S et al.: Cabergoline a first choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J. EndocrinoL Invest. (1999) 22:354–359.
   Google Scholar
• COLAO A, DI SARNO A, LANDI ML et al.: Macroprolactinoma shrinkage during cabergoline treatment is greater in naive than in patients pre-treated with other dopamine agonists: a prospective study in 110 patients. .1. Clin. Endocrinol Metab. (2000) 85:2247–2252.
   Google Scholar
• •The largest cohort of macroprolactinoma patients showing a higher shrinkage rate in naive than in non-naive patients.
   Google Scholar
• CAPPABIANCA P, LODRINI S, FELISATI G et al.: Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases. EndocrinoL Invest. (2001) 24:183–187.
   PubMed Web of Science ®Google Scholar
• CAPPABIANCA P, ALFIERI A, COLAO A et al: Endoscopic endonasal transsphenoidal approach: an addition reason in support of surgery in the management of pituitary lesions. Skull Base Surgery (1999) 9:109–117.
   PubMedGoogle Scholar
• CAPPABIANCA P, ALFIERI A, COLAO A et al: Endoscopic endonasal transsphenoidal surgery in recurrent and residual pituitary adenomas: technical note. Minim Invasive Neurosurg. (2000) 43:38–43.
   PubMed Web of Science ®Google Scholar
• MOLITCH ME: Medical treatment of prolactinomas. Endocrinol Metab. Clin. North Am. (1999) 28:143–167.
   PubMed Web of Science ®Google Scholar
• VANCE M, EVANS W, THORNER M: Bromocriptine. Ann. Intern. Med. (1984) 100:78–91.
   PubMed Web of Science ®Google Scholar
• BE VAN JS, WEBSTER J, BURKE CW, SCANLON MF: Dopamine agonists and pituitary tumour shrinkage. Endocc Rey (1992) 13:220–240.
   PubMed Web of Science ®Google Scholar
• ••Even if published 10 years ago, still a validreview on dopamine agonists and pituitary tumours.
   Google Scholar
• MOLITCH ME, ELTON RL, BLACKWELL RE et al: Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. I. Clin. Endocrinol Metab. (1985) 60:698–705.
   PubMed Web of Science ®Google Scholar
• ENJALBERT A, BOCKAERT J: Pharmacological characterization of the D-2dopamine receptor negatively coupled withadenylated cyclase in rat anterior pituitary.Phannacol (1983) 23:576–584.
   Google Scholar
• WOOD DF, JOHNSTON JM, JOHNSTON DG: Dopamine, the dopamine D2 receptor and pituitary tumors. Clin. Endocrinol (1991) 35:455–466.
   PubMed Web of Science ®Google Scholar
• VALLAR L, MELD OLESI J: Mechanisms ofsignal transduction at the dopamine D2 receptor. Trends Phannacol Sci (1989) 10:74–77.
   PubMed Web of Science ®Google Scholar
• CACCAVELLI L, CUSSAC D, PELLEGRINI I, AUDINOT V, JAQUET P, ENJALBERT A: D2 Dopaminergic receptors: normal and abnormal transduction mechanisms. Harm. Res. (1992) 38:78–83.
   PubMed Web of Science ®Google Scholar
• BUNZOW JR, VAN TOL HHM, GRANDY DK et al.: Cloning and expression of a rat dopamine D2 receptor cDNA. Nature (1988) 336:783–787.
   PubMed Web of Science ®Google Scholar
• GIROS B, SOKOLOFF P, MARTRES MP, RIOU JF, EMORINE L, SCHWARTZ JC: Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature (1989) 342:923–926.
   PubMed Web of Science ®Google Scholar
• STRADER CD, SIGAL IS, DIXON RAF: Structural basis of P-adrenergic receptor function. FASEB (1989) 3:1825–1832.
   PubMed Web of Science ®Google Scholar
• COTECCHIA S, EXUM S, CARON MG, LEFKOWITZ RJ: Regions of the a I-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc. Natl. Acad. Sci. USA (1990) 87:2896–2900.
   PubMed Web of Science ®Google Scholar
• SPADA A, NICOSIA S, CORTELLAZZI Let al: 1983 In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro-and microadenomas to dopamine and vasoactive intestinal polypeptide. Clin. Endocrinol Metab. 56:1–10.
   Google Scholar
• MCDONALD WM, SIBLEY DR, KILPATRICK BF et al.: 1984 Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2-dopamine receptors. MM. Cell Endocrinol 36:201–209.
   Google Scholar
• CROSIGNANI PG, FERRARI C: Dopaminergic treatments for hyperprolactinemia. Baillieres Clin. Obstet. Cynaecol. (1990) 4:441–455.
   PubMed Web of Science ®Google Scholar
• TROUILLAS J, CHEVALLIER P, CLAUSTRAT B et al.: Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat. Endocrinology (1994) 134:401–410.
   PubMed Web of Science ®Google Scholar
• MANTEGANI S, BRAMBILLA E, VARASI M: Ergoline derivatives: receptor affinity and selectivity. II Fannaco (1999) 54:288–296.
   PubMedGoogle Scholar
• NORDMANN R, FLUCKIGER EW, PETCHER TJ, BROWNELL J: Endocrine actions of the potent dopamine D2-agonist CV 205-502 and related octrahydrobenzo (g) quino lines. Drugs of the Future (1988) 13:951–959.
   Google Scholar
• NORDMANN R, PETCHER TJ: Octahydrobenzo [g] quinolines: Potent dopamine agonists which show the relationship between ergolines and apomorphine. J. Med. Chem. (1985) 28:367.
   PubMed Web of Science ®Google Scholar
• NORDMANN R, WIDMER A: Resolution and absolute configuration of the potent dopamine agonist N,N-Diethyl-N'-[(3a,4aa,104-1,2,3,4,4a,5,10,10a,-octahydro-6-hydroxy-1 -propy1-3-benzo quinolinyl] sulfamide. Med. Chem. (1985) 28:1540.
   Web of Science ®Google Scholar
• GAILLARD RC, NORDMANN R, PETCHER TJ, BROWNELL J: A novel octahydrobenzo [g]quinoline, CV 205–502, with potent dopamine agonist properties. Endocrinology'85. GM Molinatti, L Martini (eds). Elsevier Science Publishers B.V. (Biomedical Division, 1986), Amsterdam (1985).
   Google Scholar
• GAILLARD RC, BROWNELL J: Hormonaleffects of CV 205-502, a novel octahydrobenzo [g]quinoline with potent dopamine agonist properties. Life Sci. (1988) 43:1355–1362.
   PubMed Web of Science ®Google Scholar
• VENETIKOU MS, BURRINJM, WOODS CA, YEO TM, BROWNELL J, ADAMS EF: Effects of two novel dopaminergic drugs, CV 205-502 and CQP 201-403, on prolactin and growth hormone secretion by human pituitary tumors M vitro. Acta Endocrinol (Copenhagen) (1987) 116:287–292.
   PubMedGoogle Scholar
• CLOSSE A, CAMPS M, WANNER A, PALACIOS JM: in vivo labeling of brain dopamine D2 receptors using the high-affinity specific D2 agonist [3H] CV 205-502. Brant Res. (1988) 440:123–132.
   PubMed Web of Science ®Google Scholar
• GEORGE LD, NICOLAU N, SCANLON MF, DAVIES JS: Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas. Clin. Endocrinol (2000) 53:595–599.
   PubMed Web of Science ®Google Scholar
• VLISSIEDS DN, GILL D, CASTELOW J: Bromocriptine-induced mania? Br. Med. I (1978) 1:735–737.
   Google Scholar
• PEARSON KC: Mental disorders from low-dose bromocriptine. N Engl. J. Med (1981) 305:173.
   PubMed Web of Science ®Google Scholar
• TURNER TH, COOKSON JC, WASS JAH, DRURY PL, PRICE PA, BESSER GM: Psychotic reactions during treatment of pituitary tumors with dopamine agonist. BMJ(1984) 289:1101–1103.
   PubMed Web of Science ®Google Scholar
• EICKMANN FM: Recurrent myocardial infarction in a postpartum patient receiving bromocriptine. Clin. Cardiol (1984) 15:781–783.
   Google Scholar
• Postpartum hypertension, seizures, strokes reported with bromocriptine. FDA Drug Bull. (1984) 14:3.
   Google Scholar
• GIAMPIETRO 0, FERDEGHINI M, PETRINI M: Severe leukopenia and mild thrombocytopenia after chronic bromocriptine (CB154) administration. Am. I Med. Sci (1981) 281:169–172.
   PubMed Web of Science ®Google Scholar
• MARSHALL AW, JAKOBOVITS AW, MORGAN MY: Bromocriptine-associated hyponatraemia in cirrhosis. BMJ(1982) 285:1534–1535.
   PubMed Web of Science ®Google Scholar
• SHIMON I, MELMED S: Management ofpituitary tumors. Ann. Intern. Med. (1998) 129:472–483.
   PubMed Web of Science ®Google Scholar
• LIUZZI A, DALLABONZANA D, OPPIZZI G, VERDE GG, COZZI R, CHIODINI P et al.: Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl. J. Med. (1985) 313:656–659.
   PubMed Web of Science ®Google Scholar
• JOHNSTON DG, HALL K, KENDALL-TAYLOR P, PATRICK D, WATSON M, COOK DB: Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerized tomography. Lancet (1984) 2:187–192.
   Google Scholar
• WANG C, LAM KSL, MA TC, CHANT, LIU MY, YEUNG RTT: Long-term treatment of hyperprolactinemia with bromocriptine: effect of drug withdrawal. Clin. Endocrinol (1987) 27:363–371.
   PubMed Web of Science ®Google Scholar
• VAN'T VERLAAT JW, CROUGHS RJ: Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: effect on plasma prolactin and tumor size. Clin. Endocrinol (1991) 34:175–178.
   Google Scholar
• KLIBANSKI A, ZERVAS NT: Diagnosis andmanagement of hormone-secreting pituitary adenomas. N Engl. J. Med. (1991) 324:822–831.
   PubMed Web of Science ®Google Scholar
• LANDOLT AM, OSTERWALDER V: Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? j Clin. Endocrinol Metab. (1984) 58:1179–1183.
   Web of Science ®Google Scholar
• WEBSTER J: A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Experience (1996) 14:228–238.
   Google Scholar
• PARKES D: Side effects of bromocriptine. N Engl. J. Med. (1980) 302:749–750.
   PubMed Web of Science ®Google Scholar
• WEBSTER J, PISCITELLI G, POLLI A et al.: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea. N Engl. J. Med. (1994) 331:904–909.
   PubMed Web of Science ®Google Scholar
• DUTZ W: Drugs stimulation dopamine receptors. In: Meylers side effects of drugs, an encyclopaedia of adverse reactions and interactions. 12th edn. Dukes MNG (ed). Elsevier, Amsterdam (1992):317–318.
   Google Scholar
• REYNOLDS JEF: Dopaminergic antiparkinsonian agents. In: Martindale, the extra Pharmacopeia. 30th edn. Pharmaceutical Press, London (1993):836–850.
   Google Scholar
• EGUCHI K, KAWAMOTO K, UOZUMI T, ITO A, ARITA K, KURISU K: In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors. Endocr. J. (1995) 42:153–161.
   PubMed Web of Science ®Google Scholar
• EGUCHI K, KAWAMOTO K, UOZUMI T, ITO A, ARITA K, KURISU K: Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: M vitro culture studies. Endocr: (1995) 42:413–420.
   Google Scholar
• JOCHLE W, ARBEITER K, POST K et al.:Effects on pseudo-pregnancy, pregnancy and interoestrous intervals of pharmacological suppression of prolactin secretion in female dogs and cats. J. Reprod. Feral. (1989) 39:199–207.
   Google Scholar
• VESTERGEN JP, ONCLIN K, SILVA LD et al.: Abortion induction in the cat using prostaglandin f2 alpha and a new anti-prolactinic agent cabergoline. Reprod. Feral. (1993) 47:411–417.
   Google Scholar
• PONTIROLI AE, VIBERTI GC, MANGILI R et al.: Selective and extremely long inhibition of prolactin release in man by 1-ethy1-3- (3'-dimethylaminopropy1)-3- (6' allylergoline-8'-b-carbonyl)urea-diphosphate (fce 21336). Br. J. Clin. Pharmacol (1987) 23:433–438.
   PubMed Web of Science ®Google Scholar
• ANDREOTTI AC, PIANEZZOLA E, PERSIANI S et al.: Pharmacolkinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers.' Clin. Endocrinol Metab. (1995) 80:841–845.
   Google Scholar
• MELIS GB, GAMBACCIANI M, PAOLETTI AM et al.: Dose related prolactin-inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal and hyperprolactinemic women. J. Clin. Endocrinol Metab. (1987) 65:541–545.
   PubMed Web of Science ®Google Scholar
• CICCARELLI E, GIUSTI M, MIOLA A et al.: Effectiveness and tolerability of long-term treatment with cabergoline, a new-lasting ergoline derivative, in hyperprolactinemic patients." Clin. Endocrinol Metab. (1989) 69:725–728.
   Google Scholar
• MURATORI M, AROSIO M, GAMBINO G, ROMANO C, BIELLA 0, FAGLIA G: Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J. Endocrinol. Invest. (1997) 20:537–546.
   PubMed Web of Science ®Google Scholar
• WEBSTER J, PISCITELLI G, POLLI A et al.: The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinemic disorders: an open, uncontrolled, multicentre study. Clin. Endocrinol. (1993) 39:323–329.
   PubMed Web of Science ®Google Scholar
• BILLER BMK, MOLITCH ME, VANCE ML et al.: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. Clin. Endocrinol. Metab. (1996) 81:2338–2343.
   Google Scholar
• FERRARI C, ABS R, BEVAN JS et al: Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin. Endocrinol. (1997) 46:409–413.
   PubMed Web of Science ®Google Scholar
• COLAO A, DI SARNO A, LANDI ML et al.: Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. .1 Clin. Endocrinol. Metab. (1997) 82:3574–3579.
   Google Scholar
• COLAO A, LOMBARDI G, ANNUNZIATO L: Cabergoline. Expert Opin. Pharmacother. (2000) 1:555–574.
   PubMedGoogle Scholar
• RAINS CP, BRYSON HM, FITTON A: Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs (1995) 49:255–279.
   Google Scholar
• PAGE SR, NUSSEY SS: Cabergoline therapyof a large prolactinoma in a bromocriptine-intolerant patient. Obstet. Gynaecol. (1989) 10:156–157.
   Google Scholar
• MELIS GB, MAIS V, PAOLETTI AM et al.:Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug cabergoline. Obstet. Gynecol. (1988) 71:311–314.
   PubMed Web of Science ®Google Scholar
• BHATT MH, KEENAN SP, FLEETHAM JA et al.: Pleuropulmonary disease associated with dopamine agonist therapy. Ann. Nemo]. (1991) 30:613–616.
   PubMed Web of Science ®Google Scholar
• FRANS E, DOM R, DEMEDTS M: Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Eur. Respir. (1992) 5:263–265.
   PubMed Web of Science ®Google Scholar
• LING LH, AHLSKOG JE, MUNGER TM, LIMPER AH, OH JK: Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin. Proc. (1999) 74:371–375.
   PubMed Web of Science ®Google Scholar
• MOLITCH ME: Pituitary diseases in pregnancy. Sem. Perinatol. (1998) 22(6):457–470.
   PubMed Web of Science ®Google Scholar
• Molitch ME: Management of prolactinomasduring pregnancy. I Reproduct. Med. (1999) 44:1121–1126.
   PubMed Web of Science ®Google Scholar
• ROSSI AM, VILSKA S, HEINONEN PK: Outcome of pregnancy in women with treated or untreated hyperprolactinemia. Eur. Obstet. Gynecol. Reprod. Biol. (1995) 63:143–146.
   PubMed Web of Science ®Google Scholar
• BELTRAME D, LONGO M, MAZUE G: Cabergoline animal reproductive toxicity. Reprod. Toxicol. Submitted.
   Google Scholar
• ROBERT E, MUSATTI L, PISCITELLI G, FERRARI CI: Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod. Toxicol. (1996) 10(4)333–337.
   Google Scholar
• DE ROSA M, COLAO A, DI SARNO A et al: Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur. Endocrinol. (1998) 138:286–293.
   PubMed Web of Science ®Google Scholar
• KLIBANSKI A, NEER RIVI, BEITINS IZ,RID GWAY C, ZARVAS NT, MC ARTHUR JW: Decreased bone density in amenorrheic women. N Engl. J. Med. (1980) 303:1511–1514.
   PubMed Web of Science ®Google Scholar
• KLIBANSKI A, GREENSPAN SL: Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl. Med. (1986) 315:542–546.
   PubMed Web of Science ®Google Scholar
• •The first study indicating that osteoporosis in hyperprolactinaemia can be resolved by normalising gonadal function.
   Google Scholar
• JACKSON JA, KLEEREKOPER M, PARFITT M: Symptomatic osteoporosis in a man with hyperprolactinemic hypogonadism. Ann. Intern. Med. (1986) 105:543–545.
   PubMed Web of Science ®Google Scholar
• GREENSPAN SL, OPPENHEIM DS, KLIBANSKI A: Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. (1989) 110:526–531.
   PubMed Web of Science ®Google Scholar
• BEREZIN M, SHIMON I, HADANI M: Prolactinoma in 53 men: clinical characteristics and modes of treatment. Endocrinol. Invest. (1995) 18:436–441.
   PubMed Web of Science ®Google Scholar
• DI SOMMA C, COLAO A, DI SARNO A et al: Bone markers and bone density responses to dopamine agonist therapy in hyperprolactinemic males. I Clin. Endocrinol. Metab. (1998) 83:807–813.
   PubMed Web of Science ®Google Scholar
• COLAO A, DI SOMMA C, LOCHE S et al: Prolactinomas in children and adolescents: persistent bone loss after 2 years of prolactin normalization. Clin. Endocrinol. (2000) 52:319–328.
   PubMed Web of Science ®Google Scholar
• FERRARI C, PISCITELLI G, CROSIGNANI PG et al.: Cabergoline: a new drug for the treatment of hyperprolactinaemia. Hum. Reprod. (1995) 10:1647–1652.
   PubMed Web of Science ®Google Scholar
• CICCARELLI E, GROTTOLI S, RAZZORE P et al.: Long-term treatment with cabergoline a new long-lasting ergoline derivative in idiopathic or tumorous hyperprolactinemia and outcome of drug-induced pregnancy. J. Endocrinol. Invest. (1997) 20:547–551.
   PubMed Web of Science ®Google Scholar
• CORENBLUM B, DONOVAN L: The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Feral. Steril. (1993) 59:671–673.
   PubMed Web of Science ®Google Scholar
• KUPERSMITH MJ, ROSENBERG C, KLEINBERG D: Visual loss in pregnant women with pituitary adenomas. Ann. Intern. Med (1994) 121:473–477.
   PubMed Web of Science ®Google Scholar
• DURANTEAU L, CHANSON P, LAVOINNE A, HORLAIT S, LUBETSKI J, KUHN JM: Effects of new dopaminergic agonist CV 205-502 on plasma PRL levels and tumor size in BRC-resistant prolactinomas. Clin. Endocrinol. (1991) 34:25–29.
   PubMed Web of Science ®Google Scholar
• RAZZAQ R, O'HALLORAN DJ, BEARWELL CG, SHALET SM: The effects of CV 205-502 in patients with hyperprolactinemia intolerant and/or resistant to bromocriptine. Horm. Res. (1993) 39:218–222.
   PubMed Web of Science ®Google Scholar
• BRUE T, PELLEGRINI I, GUNZ G et al: Effects of dopamine agonists CV 205-502 in human prolactinomas resistant to bromocriptine. I Clin. Endocrinol. Metab. (1992) 74:577–584.
   PubMed Web of Science ®Google Scholar
• DELGRANGE E, MAITER D, DONCKIER J: Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur. Endocrinol. (1996) 134:454–456.
   PubMed Web of Science ®Google Scholar
• PELLEGRINI I, RASOLONJANAHARY R, GUNZ et al.: Resistance to bromocriptine in prolactinomas. Clin. Endocrinol. Metab. (1989) 69:500–509.
   Google Scholar
• •The first study investigating the molecular basis for resistance to dopamine agonists in prolactinomas.
   Google Scholar
• CACCAVELLI I, FERON F, MORANGE I et al.: Decreased expression of two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology (1994) 60:314–322.
   PubMed Web of Science ®Google Scholar
• SCILLITANI A, DICEMBRINO F, DI FAZIO P et al: In vivo visualization of pituitary dopaminergic receptors by iodine-123 methcodbenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas. Clin. Endocrinol Metab. (1995) 80:2523–2525.
   Google Scholar
• PIRKER W, RIEDL M, LUGER A et al.: Dopamine D2 receptor imaging in pituitary adenomas using Iodine-123-Epidepride and SPECT. J. Nucl. Merl (1996) 37:1931–1937.
   Web of Science ®Google Scholar
• FERONE D, LASTORIA S, COLAO A et al.: Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. j Clin. Endocrinol Metab. (1998) 83:248–252.
   PubMed Web of Science ®Google Scholar
• COLAO A, FERONE D, LASTORIA S et al.: Hormone levels and tumor size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically nonfunctioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-Methoxybenzamide. Clin. Endocrinol (2000) 52:437–445.
   PubMed Web of Science ®Google Scholar
• COLAO A, DI SARNO A, LANDI ML et al.: Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J. Clin. Endocrinol. Metab. (1997) 22:3574–3579.
   Google Scholar
• VILAR L, BURKE CW et al.: Quinagolide efficacy and tolerability in hyperprolactinemic patients who are resistant to or intolerant of bromocriptine. Clin. Endocrinol (1994) 41:821–826.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN C, BROWNELL J, BERGHT T: Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502. (1991) 125:78–91.
   Google Scholar
• NEWMAN CB, HURLEY AM, KLEINBERG DL et al: 1989 Effect of Cv 205-502 in hyperprolactinemic patients intolerant to bromocriptine. Clin. Endocrinol 31:391–400.
   PubMed Web of Science ®Google Scholar
• DELGRANGE E, CRABBE J, DONCKIER J: Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horn. Res. (1998) 49:250–253.
   PubMed Web of Science ®Google Scholar
• CANNAVO S, BARTOLONE L, BLANDINO A, SPINELLA S, GALATIOTO S, TRIMARCHI F: Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. Endocrinol Invest. (1999) 22:306–309.
   PubMed Web of Science ®Google Scholar
• DI SARNO A, LANDI ML, CAPPABIANCA P et al.: Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy. j Clin. Endocrinol Metab. (2001) 86:5256–5261.
   PubMed Web of Science ®Google Scholar
• •The sole study comparing the prevalence of resistance between CAB and BRC in a large cohort.
   Google Scholar
• COLAO A, LOCHE S, CAPPA M et al.: 1998 Prolactinomas in children and adolescents. Clinical presentation and long term follow-up. j. Clin. Endocrinol Metab. 83: 2777–2780.
   Google Scholar
• •The largest cohort published on prolactinomas in children and treatment approach.
   Google Scholar
• DISSANEEVATE P, WARNE GL: Hyperprolactinaemia and pituitary adenomas in adolescence. J. Pediatc Endocrinol Metab. (1998) 11:531–541.
   PubMed Web of Science ®Google Scholar
• COLAO A, LOCHE S, CAPPABIANCA P, DE DIVITIIS E, LOMBARDI G: Pituitary adenomas in children and adolescents. Clinical presentation, diagnosis and therapeutical strategies. Endocrinologist (2000) 10:314–320.
   Google Scholar
• DELGRANGE E, MATTER D, DONCKIER J, TOURNIAIRE J: Influence of age on the clinical presentation of prolactinomas in male patients. Gerontology (1999) 45:160–164.
   PubMed Web of Science ®Google Scholar
• LIUZZI A, OPPIZZI G: Microprolactinomas: why requiem for surgery?' Endocrinol Invest. (1996) 19:196–198.
   Google Scholar
• DI SARNO A, LANDI ML, MARZULLO P et al.: The effect of quinagolide and cabergoline, two selective dopamine receptor type-2 agonists, in the treatment of prolactinomas. Clin. Endocrinol (2000) 53:53–60.
   PubMed Web of Science ®Google Scholar
• VANCE ML, CRAGUN JR, REIMNITZ C, CHANG RJ, RASHEF E, BLACKWELL RE et al.: CV 205-502 treatment of hyperprolactinemia. I Clin. Endocrinol Metab. (1989) 68:336–339.
   PubMed Web of Science ®Google Scholar
• VANCE ML, LIPPER M, KLIBANSKI A, BILLER BM, SAMAAN NA, MOLITCH ME: Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann. Intern. Med. (1990) 112:668–673.
   PubMed Web of Science ®Google Scholar
• HOMBURG R, WEST C, BROWNELL J etal.: A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205–502, with bromocriptine in women with hyperprolactinemia. Clin. Endocrinol (1990) 32:565–571.
   Google Scholar
• CROTTAZ B, USKE A, REYMOND MJ et al.: CV 205-502 treatment of macroprolactinomas. Endocrinol Invest. (1991) 14:757–762.
   PubMed Web of Science ®Google Scholar
• VAN DER LELY, BROWNELL J, LAMBERTS SWJ: The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. Clin. Endocrinol Metab. (1991) 72:1136–1141.
   Google Scholar
• VAN DER HEIJDEN PFM, DE WITH W, BROWNELL J et al: CV 205–502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinemia. Ear: Obs. Gynecol. Reprod. Biol. (1991) 40:11–118.
   Google Scholar
• VERHELST JA, FROUND AL, TOUZEL R et al: Acute and long-term effects of once daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double blind study. Acta Endocrinol (1991) 125:385–391.
   PubMedGoogle Scholar
• Giusti M, Porcella E, Carraro A, Cuttica M, Valenti S, Giordano G: A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients." Endocrinol Invest. (1994) 17:51–57.
   PubMed Web of Science ®Google Scholar
• PERRYMAN RL, ROGOL AD, KAISER DL, MACLEOD RM, THORNER MO: Pergolide mesylate:its effects on circulating anterior pituitary hormones in man. J. Clin. Endocrinol Metab. (1981) 53:772–778.
   PubMed Web of Science ®Google Scholar
• L'HERMITE M, DEBUSSCHERE P: Potent 48 hours inhibition of prolactin secretion by pergolide in hyperprolactinemic women. Acta Endocrinol. (Copenh) (1982) 101:481–483.
   PubMedGoogle Scholar
• KLEINBERG DL, BOYD AE 3D, WARDLAW S et al.: Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl. Merl (1983) 53:737–743.
   Google Scholar
• LEMBERGER L, CRABTREE, CALLAGHAN JT: Pergolide, a potent long- acting dopamine receptor agonist. Clin. Phapnacol. Ther (1980) 27:642–651.
   PubMed Web of Science ®Google Scholar
• BERGH T, NILLIUS SJ, WIDE L: The long-acting dopamine agonist pergolide mesylate for treatment of hyperprolactinemia. Acta Eur. Feral. (1984) 15:421–424.
   PubMedGoogle Scholar
• GROSSMAN A, BOULOUX PM, LONERAGAN R, REES LH, WASS JA, BESSER GM: Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinemia. Clin. Endocrinol (Ox!) (1985) 22:611–616.
   PubMed Web of Science ®Google Scholar
• BEREZIN M, AVIDAN D, BARON E: Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs. Is]: J. Med. Sci. (1991) 27:375–379.
   PubMedGoogle Scholar
• AHMED SR, SHALET SM: Discordant responses of prolactinoma to two different dopamine agonists. Clin. Endocrinol (Ox!) (1986) 24:421–426.
   PubMed Web of Science ®Google Scholar
• LAMBERTS SWJ, QUIK RFP: A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. j Clin. Endocrinol Metab. (1991) 72:635–641.
   PubMed Web of Science ®Google Scholar
• KENDALL-TAYLOR P, HALL K, JOHNSTON DG et al.: Reduction in size of prolactin-secreting tumors in men treated with pergolide. Br. Med. J. (1982) 285:465–467.
   PubMed Web of Science ®Google Scholar